PATENT CLAIM ANALYSIS

Application Number: 16109337
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-06
Patent Classification: ["544", "262000"]

Abstract:
The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Claim (Index 25):
The method of  claim 24 , wherein (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate has an enantiomeric excess of at least 98%.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 96.0
- Lexical Diversity: 1.23333
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15283515', '13933856', '15480128', '14832962', '14440139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8375890889183447
- 35 USC 102 Novelty (BERT): 0.6157865734272825
- Combined Prediction Score: 0.8154088373692385
- Mean Citation Score: 544.4503659999998
- Max Citation Score: 583.6667
- Similarity Product: 496.74917741380926

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test